HBW Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Tightlipped On Status Of ‘SPF Determination’ Study, But Issue Is A Concern

This article was originally published in The Rose Sheet

Executive Summary

FDA’s 2016 request for contractor services to perform SPF testing on US-marketed sunscreen products has come up in litigation challenging brands’ SPF claims. The agency told Rose Sheet the issue of accurately labeled SPFs is a concern, but declined to provide further update on what it characterized as a pending matter.
Advertisement

Related Content

What’s In A Name? Babyganics Settles False Advertising Allegations To Tune Of $2.2M
SPF Fraud Cases Hard To Shake, Could Shine Light On FDA Protocol Problems
SPF Claims No More Reliable In 2018 Than Previous Years – Consumer Reports
Sunscreen Firms’ SPF Court Battles Go On, While Consumer Reports Prepares 2018 Review
Consumer Reports Blasts SPF Claims Again, But Industry's Problems May Be Bigger
FDA Strengthens Sunscreen Testing And Label Requirements

Topics

Advertisement
UsernamePublicRestriction

Register

RS121559

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel